Market Research Blog

Orthotic can be defined as the support, brace, or splint used to support, prevent, align, or to correct the functioning of movable body  parts such as neck, shoulder, wrist, knee and etc.

These devices are used to change the functioning and structural features of the neuromuscular and skeletal system. The medical field which deals with the design and manufacturing of these devices is known as Orthotics.

The orthotic devices are mainly used to overcome from the traumatic injury, congenital condition or disabling illness. This devices helps the individuals with cerebral palsy, multiple sclerosis, muscular dystrophy, spina bifida and scoliosis, and also for those who are suffering from spinal cord injuries or amputations.

Orthotic Devices – Orthotic Splints and Orthopedic Braces and Support Market: Drivers and Restraints

Presently, orthotic devices global market is driven by the aging population, increasing in the number of incidence of disabilities, growing rate of chronic and lifestyle disease.

Orthotic Devices market is driven by the aging population around the globe, increased focus on improving quality of life, rapid innovations in production and modeling technologies, growing awareness towards orthopedic ailments and rise in sports injuries. However, growing healthcare budget, poor healthcare reimbursement and payment models, and consolidation of market leaders act as a major barrier for the growth of this market.

To remain ‘ahead’ of your competitors, request for a sample

Orthotic Devices – Orthotic Splints and Orthopedic Braces and Support Market: Overview

With rapid innovations in production and modeling technologies and growing awareness towards orthopedic ailments and rise in sports injuries. The global Orthotic devices market is expected to have a healthy growth rate in the forecast period (2012-2025).

Orthotic Devices – Orthotic Splints and Orthopedic Braces and Support Market: Region-Wise outlook

Depending on geographic regions, global orthotic devices/orthotic splints and braces market is segmented into seven key regions: North America, South America, Eastern Europe, Western Europe, Asia Pacific, Japan, and Middle East & Africa.

North America held largest share in the global orthotic devices market followed by Europe and Asia Pacific. The developing nations in Asia pacific, Middle East and Africa hold huge potential for growth in the global orthotic device market, owing to developing economies and technological advances

Orthotic Devices – Orthotic Splints and Orthopedic Braces and Support Market: Key Players

• DeRoyal Industries,
• Otto Bock Holding GmbH& Co.,
• Bauerfeind AG,
• DJO Inc. and others.

The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to categories such as market segments, geographies, types, technology and applications.

The report covers exhaustive analysis on:

• Market Segments
• Market Dynamics
• Market Size
• Supply & Demand
• Current Trends/Issues/Challenges
• Competition & Companies involved
• Technology
• Value Chain

Get a Customized Scope to Match Your Need Ask an Expert- https://www.futuremarketinsights.com/ask-question/rep-gb-585

Regional analysis includes

• North America (U.S., Canada)
• Latin America (Mexico. Brazil)
• Western Europe (Germany, Italy, France, U.K, Spain, Nordic countries, Belgium, Netherlands, Luxembourg)
• Eastern Europe (Poland, Russia)
• Asia Pacific (China, India, Australia & New Zealand)
• Japan
• Middle East and Africa (S. Africa, N. Africa)

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

Orthotic Devices – Orthotic Splints and Orthopedic Braces and Support Market: Segmentation

Orthotic devices market is segmented into following types:

• Orthopedic Braces and Support
• Upper Extremity Braces and Support
• Shoulder Braces and Support
• Neck Braces and Support
• Elbow Braces and Support
• Wrist Braces and Support
• Spinal Braces and Support
• Low Extremity Braces and Support
• Knee Braces and Support
• Ankle Braces and Support
• Hip Braces and Support
• Orthotic Splints
• Upper Extremist Splints
• Lower Extremist Splints

For in-depth competitive analysis Buy Now – https://www.futuremarketinsights.com/checkout/585

Report Highlights:

• Detailed overview of parent market
• Changing market dynamics in the industry
• In-depth market segmentation
• Historical, current and projected market size in terms of volume and value
• Recent industry trends and developments
• Competitive landscape
• Strategies of key players and products offered
• Potential and niche segments, geographical regions exhibiting promising growth
• A neutral perspective on market performance
• Must-have information for market players to sustain and enhance their market footprint

Zipper Pouch Market Snapshot

Newly released data by Future Market Insights (FMI), predicts the zipper pouch demand to improve by 4.2% in 2021 reaching volume of 44.3 billion units.

The overall valuation is expected to top US$ 2.1 billion in 2021, with the market continues exhibiting growth at a CAGR of 5.3% between 2021 and 2031. Rising in-store sales will remain a chief growth driver as consumers show greater keenness for competently packaged food items.

To remain ‘ahead’ of your competitors, request for a sample @ https://www.futuremarketinsights.com/reports/sample/rep-gb-4773

While improvement is global sales is on cards, developed countries are expected to remain primary markets. Against this backdrop, FMI predicts demand in North America to surpass US$ 543.3 million in 2021. The U.S. will emerge as a highly lucrative pocket for sales within North America, exhibiting 4.1% year on year growth in the same year.

Zipper pouches are accepted worldwide because they are both re-sealable and re-usable. These products also offer strong barriers to external atmosphere and temperature fluctuations. Applications of zipper pouches in the pharmaceutical, cosmetics, and personal care industries are gaining traction.

Marketers and retailers are able leverage zipper pouches to fulfil demand for packaging aesthetics. Also, consumer convenience through clear packaging attributes is likely to fuel demand for the foreseeable future.

In recent years, manufacturing giants have shifted their focus on the use of recyclable raw materials such as polyethylene (PE), polyvinyl chloride (PVC) and polypropylene (PP). Improvements in machinery have enabled large scale production with minimal waste.

Largely, the zipper pouch market is projected to grow supported by the usage of sustainable materials and green practices by producers and end-use industries.

For More Information or Query or Customization Before Buying, Visit: https://www.futuremarketinsights.com/customization-available/rep-gb-4773

Key Takeaways from the Zipper Pouch Market

Study Stand up zipper pouches account for more than 79% market value, owing to relative ease of use. In North America, the U.S. holds a market share of almost 89% in 2021, driven by a matured packaged food sector. The zipper pouch market in Germany is anticipated to exhibit a growth rate of 5% supported by the large-scale manufacturing sector of the country. India is a fast-growing market in APEJ, driven by a large consumer base and changing consumer food and beverage consumption trends. Zipper pouches are most widely used packaging various types of food products, as it holds almost 76% of market share in the year 2021.

“Expansion of the global zipper pouch market is largely driven by a surge in demand for packaged foods. The need to preserve food items and offer protection against harsh atmospheric conditions have aided developments in the industry. Most manufacturers are focusing eco-friendly raw materials and sustainable practices for producing making zipper pouches” says the FMI analyst.

Zipper Pouch Market Landscape

Key players contribute 20-30% of the global market. Market leaders are largely engaged in strategies to expand production capacity while investing in material innovations to improve on packaging barrier properties.

Berry Global Group, Amcor plc and Rengo Co. Ltd., Transcontinental Inc., C.I. Takiron Corporation and Novolex Holdings, LLC are some of the leading players in the zipper pouch market.

For Information On The Research Approach Used In The Report, Ask Analyst @ https://www.futuremarketinsights.com/askus/rep-gb-4773

Zipper Pouch Market Report

Future Market Insights, in its new report, offers an unbiased analysis of the zipper pouch market, analyzing historical demand from 2012-2020 and forecast statistics for 2021-2031. The study reveals growth projections on the zipper pouch market on the basis of product type (standup zipper pouch and flat zipper pouch), material type (plastic, aluminum laminates, paper, and others), end use (food, pharmaceuticals, cosmetics & personal care, and others) and the closure type (slider zip and press to close) across seven regions.

About Us

Future Market Insights (FMI) is a leading market intelligence and consulting firm. We deliver syndicated research reports, custom research reports and consulting services which are personalized in nature. FMI delivers a complete packaged solution, which combines current market intelligence, statistical anecdotes, technology inputs, valuable growth insights and an aerial view of the competitive framework and future market trends.

Contact Us
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
F: +1-845-579-5705
T (UK): + 44(0)20-7692-8790

For Sales Enquiries: sales@futuremarketinsights.com
For Media Enquiries: press@futuremarketinsights.com
Website: https://www.futuremarketinsights.com

Acetaminophen API (paracetamol), or Tylenol, is used as in the first-line drug therapy in pain conditions. The API when combined with drug shows antipyretic & analgesics effect. Acetaminophen is found in over the counter (OTC) sensitivity drugs, cold meds, sleep medication, pain relievers and so on.

The Indian government has confined the export of 27 active pharmaceutical ingredients (APIs) and completed portion drugs made with those APIs because of Covid-19. Johnson and Johnson’s (New Brunswick, NJ, US) Tylenol (acetaminophen/paracetamol) is among the medications whose supply chain will be influenced.

The medication can be administered in patients who are bigoted to salicylates and those with hypersensitive propensities, including bronchial asthmatics. It comes under the NSAIDs (nonsteroidal anti-inflammatory drugs) category because of its capacity to repress the cyclooxygenase (COX) pathways.

The request will influence worldwide pharmaceutical supply chains. India is a crucial area of pharmaceutical manufacturing for the drugs market in different countries. The nation houses drug manufacturing units possessed by contract fabricating associations (CMOs) and others claimed by local and global biopharma organizations for in-house manufacturing

To remain ‘ahead’ of your competitors, request for a sample

Acetaminophen API Market: Drivers and Restraints:

The easy availability of this drug is boosting the growth of the Acetaminophen API market.  Meanwhile increasing usage of drugs for pain-relieving effects is propelling the growth of the Acetaminophen API market. Moreover, rising incidences of accidents, surgeries are further boosting the Acetaminophen API market.

Moreover, people addiction to using these drugs for rapid pain relief also fuelling the growth of the Acetaminophen API market. Additionally, environmental conditions, lifestyle changes & dietary habits modifications are responsible for a variety of disorders which increases the consumption of these drugs.

However, the excessive dosage can cause toxicity which can lead to serious complications such as liver diseases, fertility issues, carcinogenesis & mutagenesis which can hamper the growth of the Acetaminophen API market.

Acetaminophen API Market: Overview

The usage of acetaminophen grade is higher due to its wide utilisation in the drug development process. While it is widely used in the pharmaceutical industry as a pain killer which offers a lucrative opportunity for the growth of the Acetaminophen API market in the forecasted period. Aside from this, the acetaminophen drug is combined with various drug and available in various forms, but it is mostly available in the form of extended-release tablets for showing analgesics effects. But heavy usage of this drug can cause serious adverse effects & can build toxicity which leads to other diseases.

Acetaminophen API Market: Regional Wise Outlook

Geographically, the Acetaminophen API market is divided into seven regions viz. North America, Latin America, Western Europe, Eastern Europe, Asia Pacific, China, Japan & the Middle East and Africa.  Asia-Pacific is expected to dominate the global acetaminophen API market followed by North- America & Europe.

Asia-Pacific is dominating the global acetaminophen API market due to higher population rate which led to increased accidental cases, surgeries & various disorders, thus the demand for the drugs is increasing in this region which is boosting the Acetaminophen API regional market. While the increasing healthcare conditions & awareness amongst the people is further fuelling the Acetaminophen API market.

Rapid development & Advancements along with the changing environmental conditions is going to offer a lucrative opportunity for the growth of acetaminophen API market in North America during the forecasted period.

Get a Customized Scope to Match Your Need Ask an Expert- https://www.futuremarketinsights.com/ask-question/rep-gb-12465

Acetaminophen API Market: Key Market Participants

The key participants operating in the global acetaminophen API market identified across the value chain are

• BOC Sciences
• Tianjin Bofa Acetaminophen
• Mallinckrodt plc
• Kemcolour International
• Changshu Huagang Acetaminophen
• Haohua Industry
• Kangle Acetaminophen
• Angene International Limited
• Anhui BBCA Acetaminophen
• Granules India
• Hebei Jiheng Acetaminophen
• Glosel India Impex Pvt Ltd. from India
• Flare S.A. from Switzerland
• Silverline chemicals ltd from India
• Emkay Pharma Pvt Ltd from India
• Atabay K.S.V.T. from Turkey
• Anqiu Lu’An from China
• United Pharma Industries Co Ltd from China
• Farmson from India
• Liaoyuan City Baikang from China

The players working in the worldwide acetaminophen API market are concentrating on the drug discovery i.e. by combining the API with various other extracts for the development of new therapeutic medication which would be helpful in prevention & cure of various disorders. Currently, the company are focusing at the collaborations, mergers & acquisitions with other companies.

The report covers exhaust analysis on:

• Acetaminophen API Market Segments
• Acetaminophen API Market Dynamics
• Market Size
• Supply & Demand
• Current Trends/Issues/Challenges
• Competition & Companies involved
• Technology
• Value Chain

Regional analysis includes:

• North America (U.S., Canada)
• Latin America (Mexico. Brazil)
• Western Europe (Germany, Italy, France, U.K, Spain)
• Eastern Europe (Poland, Russia)
• Asia Pacific (India, China ASEAN, Australia & New Zealand)
• Japan
• The Middle East and Africa (GCC Countries, S. Africa, Northern Africa)

Report Highlights:

• Detailed overview of the Healthcare market
• Changing Acetaminophen API Market dynamics in the industry
• Below the Acetaminophen API Market -depth market segmentation
• Historical, current, and projected market size in terms of volume and value
• Below the Acetaminophen API Market recent industry trends and developments
• Competitive landscape
• Strategies of key players and products offered
• Potential and niche segments, geographical regions exhibiting promising growth
• A neutral perspective on market performance
• Must-have information for market players to sustain and enhance their market footprint

For critical insights, request for PDF Brochure: https://www.futuremarketinsights.com/reports/brochure/rep-gb-12465

Acetaminophen API Market Segmentation:

The global Acetaminophen API market has been segmented based on product form, type, application, end-user and geography.

Type

• Veterinary Drug Grade
• Acetaminophen Grade

End-user

• Pharmaceuticals Industry
• Research labs
• Educational institutes
• Others

Product form

• Tablets (film-coated, extended-release)
• Oral Solution
• Suppository
• Injection
• Others

Indications

• Antipyretic
• Analgesics
• Others

Parenteral Packaging Market Snapshot

Future Market Insights (FMI) in its market analysis projects the parenteral packaging market to grow at 5.5% CAGR during the forecast period 2021-2031. Driven by the rising necessity of effective packaging solutions for therapeutic drugs without compromising their potency, the parenteral packaging market is forecast to reach the market valuation of US$ 11,460 Mn in 2021.

North America is expected to provide lucrative growth opportunities backed by increasing healthcare spending and rising production rate of parenteral packaging in U.S. Spurred by this, the North America parenteral packaging worth is projected to expand at 4.3% CAGR in 2021.

To remain ‘ahead’ of your competitors, request for a sample @ https://www.futuremarketinsights.com/reports/sample/rep-gb-1258

Companies are shifting towards prefilled and ready-to-use containers and this is expected to augment the usability of parenteral products in self-medication.

As such, the global market for parenteral packaging is set to witness significant growth in the next 10 years, as estimated in a study by Future Market Insights. According to a report released by the leading market research firm, the global parenteral packaging market is set to exceed US$ 11460 Mn by the end of 2021.

Exhibiting a growth rate of 5.5% in the coming decade, revenue from the sales of parenteral packaging products is slated to experience around 6% year-on-year growth rate in 2021. Sustainability is the buzzword here – manufacturers are steadfast in their focus on addressing environmental concerns; which probably explains the near-death of plastic as a preferred material for parenteral packaging, owing to environmental issues associated with the disposal of plastic parenteral packaging products.

Innovation to Take Centre Stage in the Manufacturing of Parenteral Packaging Products; Automation to Underpin Core Production Processes

With technology having seeped through the global industry fabric, the market for parenteral packaging products is witnessing a new era of advanced processing techniques powered by automation in the packaging industry.

For More Information or Query or Customization Before Buying, Visit: https://www.futuremarketinsights.com/customization-available/rep-gb-1258

Advanced automation in manufacturing processes has brought in notable modifications pertaining to the provision of drugs to patients, and this integration of automation into core manufacturing systems is trending the global parenteral packaging market.

Manufacturers are also focusing on deploying high quality, contamination free processes to assemble parenteral packaging containers. These processes seek to eliminate incidences of reactions between the material used to manufacture the containers and the actual content (drugs) of the containers, thereby preventing harmful effects on patients consuming the drugs.

Several product recalls in the past have forced manufacturers of parenteral packaging products to select the best material to manufacture containers, and this factor is acting in favour of revenue growth of the global parenteral packaging market.

Ready-to-Fill Formats and Automated Assembly Lines Trending the Global Parenteral Packaging Market

On the back of sustainability drives by global governments, manufacturers of parenteral packaging products are changing their operations by integrating automated systems in their assembly lines.

A strategic shift from manual to automatic packing lines is bringing in enhanced process efficiency and reducing dependency on manual labour, thereby creating pathways for cost-effectiveness in the long run. Further, the rapidly rising demand for prefilled syringes is benefitting the global parenteral packaging market.

Specific requirements from the healthcare industry for speciality packaging products such as IV pre-mixed systems and single-use vials is also expected to bolster revenue generation in the global market for parenteral packaging in the coming years.

For critical insights on this market, request to ask an expert here @ https://www.futuremarketinsights.com/askus/

Newer Raw Material Options to Create Increased Growth Opportunities for Manufacturers of Parenteral Packaging Products

Over the years, conventional raw materials used to manufacture parenteral packaging products have witnessed several advancements. Add to this the introduction of newer types of material to manufacture parenteral packaging containers, and the global market is suddenly a hotbed of opportunities for manufacturers.

The global parenteral packaging market is witnessing strategic collaboration between manufacturers and suppliers for both the sourcing of appropriate raw materials and the final packaging formats.

For instance, polymers such as cyclic olefin polymers (COP) and cyclic olefin copolymers (COC) are being sought after in large numbers, owing to their inherent advantages over conventional plastic and glass used to manufacture parenteral packaging containers.

The introduction of better raw material types supports increased sophistication in drug delivery technologies, thereby helping manufacturers up their revenue standing in the global market. Needless to say, this is positively impacting revenue growth of the global parenteral packaging market.

For Information On The Research Approach Used In The Report, Ask Analyst @ https://www.futuremarketinsights.com/askus/rep-gb-1258rep-gb-1258

Key Questions Answered in the Report

• What is parenteral packaging market size?

  Driven by increasing demand for therapeutic drugs storage provisions, the parenteral packaging market size is forecast to reach US$ 11,460 Bn in 2021

• At what rate did the parenteral packaging market expand in the last five years?

  Between 2016 and 2020, the parenteral packaging sales surged at a 4.6% CAGR backed by increasing demand for self administered drugs and medicines for chronic ailments.

• What are the key trends shaping the parenteral packaging market?

  Growing emphasis towards multi-compartment parenteral packaging for faster distribution of medications across the globe is the key trend shaping the market.

• What are the key factors driving parenteral packaging market demand?

  Rising prevalence of chronic ailments and high demand for vaccines to tackle epidemics and pandemics will remain the chief growth driver. The market also will gain from rising spending on advanced healthcare.

• What is the North America parenteral packaging market outlook?

  Demand registered in North America will continue rising, backed increasing sales and production of parenteral packaging in the U.S, the North America market will expand at 4.3% CAGR in 2021.

About Us

Future Market Insights (FMI) is a leading market intelligence and consulting firm. We deliver syndicated research reports, custom research reports and consulting services which are personalized in nature. FMI delivers a complete packaged solution, which combines current market intelligence, statistical anecdotes, technology inputs, valuable growth insights and an aerial view of the competitive framework and future market trends.

Contact Us
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
F: +1-845-579-5705
T (UK): + 44(0)20-7692-8790

The global demand for PD1/PDL1 inhibitors has been marginally impacted by the coronavirus pandemic in 2020, with disruptions and delays in supply chains owing to logistical and transport issues. According to a recent study by Future Market Insights (FMI), the long-term prospects of the industry is likely to remain very positive, with investments growing for cancer treatment research and emphasis on biologics in the pharma industry.

According to FMI analysts, PD1/PDL1 inhibitors are anticipated to play increasingly important roles in cancer treatment procedures, owing to lower toxicity levels in comparison to other treatment alternatives, and better compliance with safety standards being implemented by regulatory bodies in different countries.

To remain ‘ahead’ of your competitors, request for a sample

The industry has witnessed exponential growth in the past few years on account of investments into research for biologics in the pharmaceutical sector and the potential application of immunity check point inhibitors, and promising results from clinical trials against conditions such as non-small cell lung cancer, melanoma, and head & neck squamous cell cancer among others.

Pembrolizumab and nivolumab inhibitors are being used increasingly in the healthcare sector owing to regulatory approval for treating a wider range of cancers in comparison to other PD1/PDL1 inhibitor variants. Applications towards treating non-small cell lung cancer will remain a major contributor to industry revenues.

However, high costs associated to cancer treatment in hospital settings, coupled with long durations and strict regulations associated with the approval process of PD1/PDL1 inhibitor products are major challenges to market participants.

The report by FMI offers a detailed market overview, covering critical growth dynamics. Some of the top takeaways from the study include:

The PD1/PDL1 inhibitors Market was valued at US$ 21.8 Bn in 2019, with growth diminishing slightly during the coronavirus crisis

Pembrolizumab inhibitors remain in high demand owing to regulatory approval for applications for a wider range of cancer treatments

Sales and distribution through hospital pharmacies will remain higher than retail and online pharmacy alternatives, owing to robust supply chains and larger inventories

Sales in North America will remain critical to market growth through 2030. However, Asian countries are reflecting lucrative growth opportunities with a vast population base and investments in healthcare infrastructure modernization

“PD1/PDL1 inhibitors are a number of fairly new checkpoint inhibitor cancer treatment drugs which block select immune checkpoint proteins in cells that are at risk to tumours and are emerging as a front-line treatment in immunotherapy for several types of cancer, driven by healthcare research in North America and Europe,” said a lead analyst at FMI.

Get a Customized Scope to Match Your Need Ask an Expert- https://www.futuremarketinsights.com/ask-question/rep-gb-12644

Covid-19 Impact on the PD1/PDL1 Inhibitors Market

The coronavirus pandemic is estimated to have a moderate impact on the PD1/PDL1 inhibitors market in the short term. Challenges are likely to arise in terms of supply chain disruptions in terms of raw materials and product delivery owing to logistical and transportation delays.

Further, governments and healthcare facilities around the world are redirecting essential resources towards handling the pandemic, which is limiting the scope of application for cancer treatments through PD1/PDL1 inhibitors.

The uncertainty over the duration and the severity of the pandemic is a key challenge that players in the PD1/PDL1 inhibitors market will have to contend with in the months to come. However, the higher risk of comorbidities for cancer patients also affected by the coronavirus is expected to partially alleviate challenges in the industry. Recovery of the sector is likely to be strong as cancer cases remain prevalent across the globe.

Who is Winning?

In the report, FMI has scrutinized the different strategies businesses involved in the PD1/PDL1 inhibitors market have employed. Top players in the industry have largely invested in product development and research efforts including major clinical trials. Also, capacity expansions along with strategic partnerships and acquisitions have gained importance among the market players.

Some of the leading players in the PD1/PDL1 inhibitors market include

Bristol-Myers Squibb
Merck & Co. Inc.
F. Hoffmann-La Roche AG
Merck KGaA
Pfizer Inc.
and AstraZeneca.

Key Segments

Product type

Nivolumab

Pembrolizumab

Atezolizumab

Avelumab

Durvalumab

Indication

Melanoma

Non-Small Cell Lung Cancer (NSCLC)

Renal Cell Carcinoma (RCC)

Head and Neck Squamous Cell Cancer (HNSCC)

Bladder Cancer

Merkel Cell Carcinoma (MCC)

Others

Distribution Channel

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

For critical insights, request for PDF Brochure: https://www.futuremarketinsights.com/reports/brochure/rep-gb-12644

Regional Outlook

North America (U.S., Canada)

Latin America (Brazil, Mexico, Argentina, Rest of LATAM)

Europe (Germany, Italy, France, U.K., BENELUX, Spain, Russia, Rest of Europe)

South Asia (India, Thailand, Indonesia, Malaysia, Rest of South Asia)

East Asia (China, Japan, South Korea)

Oceania (Australia, New Zealand)

Middle East & Africa (GCC Countries, Turkey, South Africa, Rest of MEA)

Timely drug delivery is the cornerstone of an effective healthcare infrastructure. Rising prevalence of chronic and infectious ailments have accelerated production of prescription drugs, prompting vendors to develop effective distribution networks.

Advancements in consumer touch points and supply chains, including e-commerce, convenience stores and retail stores have greatly altered the prescription delivery services landscape. Advancements such as drone-based delivery and tracker based prescriptions are helping usher in smooth customer experience.

Furthermore, advanced prescription delivery systems have not only assisted in providing round-the-clock customer services but also helped manage dosage, therapy adherence and provide feedback to clinicians.

Prescription Delivery Services Market- Key Takeaways

Diabetic prescription drugs to hold major sway, poised to capture 36.7% market share by 2030 Ease of access to drugs addressing chronic conditions is slated to drive retail pharmacy growth to greater heights North America to expand stupendously at a CAGR of 18.4% from 2020-2030, attributed to the presence of multiple convenience and pharmacy stores Global prescription delivery services market to reach US$ 434.3 Mn by 2030-end

“Adoption of self-checkout kiosks and medicine dispensing machines shall enhance medicine purchasing experience of customers, permitting vendors to experience greater customer loyalty,” concludes the FMI analyst.

To remain ‘ahead’ of your competitors, request for a sample

COVID-19 Impact Insights

The COVID-19 pandemic has generated fertile ground for the prescription delivery services market. The imposition of nationwide lockdowns to enforce social distancing have reduced footfalls across conventional pharmacies. This has compelled patients to rely on online retail platforms to avail their medicines.

Furthermore, heightened vulnerability of geriatrics suffering from co-morbidities to the coronavirus has necessitated stockpiling of essential medicines, thus keeping the need for prescription delivery services afloat throughout the pandemic’s duration. This panic buying behavior shall usher in an 80% y-o-y growth.

Growth is especially anticipated to be robust across the U.S, China and India, countries with the highest rates of infections. Collectively accounting for 40% of the global infection rate, these countries have witnessed an unprecedented increase in hoarding prescription medicines by individual households. This shall continue until the latter-half of 2021.

Key Players:

Walmart Stores Inc.

Walgreens Co.

CVS Health

Express Scripts Holding Company

Giant Eagle Inc.

DocMorris (Zur Rose Group AG)

Rowlands Pharmacy

OptumRx Inc.

Ali Health

Kroger Co.

Amazon (PillPack)

Market Witnessing Entry of e-Commerce Players

The Prescription Delivery Service Market is witnessing entry of e-Commerce, pharmacy and retail chains, albeit at a local or regional level. Technological developments, new product launches and collaborations characterize some critical expansion strategies of market players.

Some of the key players in the Prescription Delivery Service Market are: Walgreens Co., Walmart Stores Inc., CVS Health, Giant Eagle Inc., Express Scripts Holding Company, Ali Health and Kroger Co. to name a few.

Besides these established players, several startup companies are also emerging as potential game changers in the industry. These include NetMeds, Kfyao, Capsule, Myra Medicines, NURX, MedAvail, Zipdrug, Insightfil and ScriptDrop to name a few.

Walgreens, a prominent retail pharmaceutical distributor, has a robust presence in the global prescription delivery services market. The company offers refills, auto refills, drug information and home delivery services.

In 2017, the company acquired Rite Aid for a sum of US$ 5.2 billion, resulting in the merger of two of the United States’ three largest pharmacy chains.

Get a Customized Scope to Match Your Need Ask an Expert- https://www.futuremarketinsights.com/ask-question/rep-gb-12534

More Insights on the Prescription Delivery Services Market

A recent market study published by Future Market Insights on the Prescription Delivery Services Market includes global industry analysis for 2015-2019 & opportunity assessment for 2020-2030, and delivers a comprehensive assessment of the most important market dynamics. The report has been segmented on the basis of disease indication (therapeutic drugs (diabetes, hypertension & cholesterol disorders), wellness supplements, OTC drugs and diagnostic drugs) and distribution channel (pharmacy stores, healthcare institutions, clinics and research institutions) across seven geographies (North America, Latin America, Europe, South Asia, East Asia, Oceania and MEA).

Prescription Delivery Services Market Segmentation

Disease Indication

Therapeutic Drugs

Diabetes

Hypertension

Cholesterol Disorders

Wellness Supplements

OTC Drugs

Diagnostic Kits

Distribution Channel

Pharmacy Stores

Retail Pharmacy

Drug Stores

Healthcare Institutions

Clinics

Research Institutes

Region

North America (U.S & Canada)

Latin America (Brazil, Mexico & Rest of Latin America)

Europe (Germany, France, Italy, U.K, Spain, BENELUX, Russia & Rest of Europe)

South Asia (India, Malaysia, Thailand, Indonesia & Rest of South Asia)

East Asia (China, Japan & South Korea)

Oceania (Australia & New Zealand)

Middle East & Africa (GCC, Northern Africa, South Africa & Rest of MEA)

The global zika virus testing market experienced a moderate incline, experiencing a CAGR of just above 2% between 2017 and 2020, being valued at a little over US$ 4 billion, as per ESOMAR-certified firm Future Market Insights (FMI) latest report on the landscape. Growth was majorly underpinned by the introduction of numerous point-of-care powerful testing approaches to facilitate timely detection of the virus.

According to FMI’s analysis, clinicians have been exhibiting a high preference towards enzyme linked immunosorbent assay (ELISA) tests. Compared to other immunoassay methods, ELISA tests are more accurate, are considered highly sensitive, specific and compare favorably with other methods used to detect substances in the body, such as radioimmune assay (RIA) tests.

To remain ‘ahead’ of your competitors, request for a sample

Prominent players are experiencing immense growth opportunities across tropical regions, attributed to the high concentration rate of the zika virus across such regions as the Caribbean, Central America, Africa and the Asian sub-continent. Players such as EUROIMMUN have emerged at the forefront, being the first diagnostics company to provide a testing approach to detect the zika virus. Its product lines include the Anti-Zika Virus ELISA (IgA or IgG or IgM or IgAM) fully automatable test and the IIFT Arbovirus Fever Mosaic 2 (IgG or IgM) test.

EUROIMMUN US Inc.

Creative Diagnostics

Quest Diagnostics

Artron Laboratories Inc.

RapiGEN Inc.

GenBody Inc.

JAJ International Inc.

LumiQuick Diagnostics Inc.

Biocan Diagnostics Inc.

NECTAR LIFESCIENCES LTD.

Luminex Corporation

ARUP Laboratories

Abbott Molecular Inc.

Hologic

Vela Diagnostics

 

Get a Customized Scope to Match Your Need Ask an Expert- https://www.futuremarketinsights.com/ask-question/rep-gb-2913

Key Takeaways from FMI’s Zika Virus Testing Market Study

By test type, ELISA-based zika virus testing surpassed US$ 4 billion until 2020

By end-user, private commercial laboratories to remain primary point of contact for availing zika virus testing

Multiple regulatory approvals for various testing approaches by the FDA to bolster US zika virus testing market growth

Brazil to attract major zika virus testing providers amid increasing governmental initiatives to contain its spread

Growing focus on pregnant women’s health to accelerate testing volumes in Puerto Rico

UK to experience limited uptake amid the non-notifiable nature of the disease due to limited outbreaks

 

“Rising government initiatives to address possible suspected infection cases are providing a wide platform for the introduction of advanced zika virus testing approaches, providing key players a chance to expand their footprints across key geographies,” says the FMI analyst.

Competitive Landscape

Prominent zika virus testing manufacturers are reliant on offering advanced testing approaches in order to yield quicker results so as to facilitate timely treatment. Besides, key research laboratories and organizations also emphasize on expanding their testing capabilities by virtue of strategic acquisition and collaboration agreements.

In 2017, the US FDA issued an Emergency Use Authorization (EUA) to authorize the RealStar® Zika Virus RT-PCR Kit for the in vitro qualitative detection of Zika virus with specified instruments. This test is offered by Altona Diagnostics GmbH, and tests presence of the virus in human serum, EDTA plasma and/or urine.

Similarly, ARUP Laboratories offers both serology and RT-PCR tests for detecting the zika virus. The former is called the Zika Virus IgM Antibody Capture (MAC) based on the ELISA technique. In the latter case, the test is conducted by collecting patients’ blood or urine samples.

Key Segments Covered

Test Type

Rapid IgG/IgM Test

ELISA Test

End-User

Hospitals & Clinics

Private Commercial Laboratories

Government/Publicly Funded Programs

For critical insights, request for PDF Brochure: https://www.futuremarketinsights.com/reports/brochure/rep-gb-2913

Region

North America & Europe (US, UK, Germany, Spain, France, Italy and Rest of Europe)

Latin America (Brazil, Mexico, Colombia  and Rest of LATAM)

Central America (Costa Rica, Nicaragua, Guatemala and Rest of Central America)

Caribbean (Puerto Rico and Rest of the Caribbean)

South East Asia (Thailand, Singapore, Vietnam and Rest of South East Asia)

Rest of the World (North Africa and South Africa)

Laparoscopy Suction Irrigation Pumps are likely to remain the top selling product type, whereas developing economies are projected to demonstrate impressive revenue growth in coming years.

Providing a brief overview of the FDA regulations for Class II medical devices such as endoscopes, a new study presented by Future Market Insights offers an exhaustive assessment of the global endoscopy fluid management systems landscape for a 10-year projection period, 2018-2028.

According to the FMI study, as the Tier 1 players continue to contribute over 70% share of the market revenue, the global endoscopy fluid management systems landscape remains a highly consolidated space.

The report covers extensive profiling of the top four performers including a few of the biggest industry names such as Stryker Corporation and Olympus Corporation. However, research indicates that even local players have strong penetration in regional markets.

To remain ‘ahead’ of your competitors, request for a sample

Top 3 Insights from Key Players Analysis

While a majority of companies are focusing on new product launches, strategic mergers and acquisitions are likely to emerge the most profitable developmental decisions in the near future. Most of these strategic moves will be primarily directed to address the high price point pressure associated with endoscopy fluid management systems that often affects revenue growth in developing economies. Major hospital networks in developed regional markets are witnessing M&A between hospitals, which is likely to shape costing of medical devices such as endoscopy fluid management systems – eventually slashing down the profitability margins of manufacturers. “Constantly increasing chronic disease instances, coupled with immense technological advances in the field of endoscopy, is prominently driving the US$ 342 Million market for endoscopy fluid management systems (or irrigation pumps) in recent years,” says a senior research analyst at the company.

Prominent Players:

Karl Storz GmbH & Co KG
Olympus Corporation
Richard Wolf GmbH
Smith & Nephew
Stryker Corporation
DePuy Synthes (Johnson & Johnson Services Inc.)
Cantel Medical Corporation
Medtronics Plc.
B. Braun Medical Inc. and Hologic Inc

Get a Customized Scope to Match Your Need Ask an Expert- https://www.futuremarketinsights.com/ask-question/rep-gb-4358

Top 5 Insights from Segmental Analysis

With maximum use in laparoscopic procedures, endoscopy fluid management systems continue to register maximum revenue generation through sales of laparoscopy suction irrigation pumps, followed by laparoscopy fluid management systems.

Based on the modality of endoscopy fluid management systems, the Benchtop holds a substantial market value share.

Hospitals register the highest consumption of endoscopy fluid management systems.

Owing to a massive number of cancer survivors in the US, North America’s market for endoscopy fluid management systems is currently accounting for the largest revenue share in the global landscape, followed by Asia Pacific and Europe.

MEA and Latin America are likely to represent a significant incremental opportunity, according to FMI study.

Healthy Year over Year Revenue Growth Projected for Asia Pacific

APAC has become the hotspot for leading medical device companies, which is further intensified by dramatically growing medical tourism sector. Across APAC, Japan is likely to account for substantial revenue generation, enabling the regional market secure second spot in the global endoscopy fluid management systems landscape. FMI projects over 7% year on year revenue growth in 2020 and beyond, for this regional market.

Government Regulations Favor Market Growth in Latin America

Latin American market for endoscopy fluid management systems is thriving at a promising pace owing to favorable government initiatives regarding endoscopic procedures and medical device marketing. Noteworthy demand for laparoscopy suction irrigation pumps within the region is identified to be responsible for the rapid revenue growth of endoscopy fluid management systems marketplace across Latin America.

Egypt’s End Users Drive Market Growth in MEA

The market for endoscopy fluid management systems in MEA is prominently driven by the improving regulatory landscape related to the marketing of medical devices, pushed further by impressive sales of laparoscopy suction irrigation pump based endoscopy fluid management systems. FMI spots higher market attractiveness in Egypt owing to the presence of a large number of end users. However, poor operational environment still remains a major growth barrier for the region.

For in-depth competitive analysis Buy Now – https://www.futuremarketinsights.com/checkout/4358

Segmentation

The report offers a comprehensive taxonomy of the endoscopy fluid management systems market based on product type, end user, modality and region. Endoscopy fluid management systems are used for various types of endoscopic surgeries such as hysteroscopy and laparoscopy.. End-user segments in the endoscopy fluid management systems market include hospitals, ambulatory surgical centers and other end users, such as specialty clinics & diagnostic centers.

From a regional perspective, the endoscopy fluid management systems market has been analyzed across North America, Latin America, Europe, Asia Pacific and Middle East & Africa.

Nearly 70% of the psoriasis patient population is prone to psoriatic arthritis, and up to 20% of arthritis patients are susceptible to acquire psoriasis, according to the recent findings of the Arthritis Foundation.

The rate of increasing burden of psoriasis and psoriatic arthritis on healthcare industry has been boosting clinical research in the field of psoriatic arthritis, in recent years.

Sustained adoption of conventional disease modifying anti-rheumatic drugs (DMARDs), especially in cost sensitive regions, is projected to push the demand for psoriatic arthritis treatment in coming years.

Psoriatic Arthritis (PsA) Treatment Market – Key Research Findings

Global Psoriatic Arthritis (PsA) treatment market size in 2018 – nearly US$ 7,800 Mn.

The Psoriatic Arthritis (PsA) treatment market is expected to grow at an approximate CAGR of 7.2% over 2018-2028.

North America and Europe are expected to remain the largest regional markets for Psoriatic Arthritis (PsA) treatment

North America and Europe are among the prominent regions in the Psoriatic Arthritis (PsA) treatment market owing to the increasing adoption of biologics and biosimilars, along with the growing adoption of combination treatment for psoriatic arthritis.

To remain ‘ahead’ of your competitors, request for a sample

Prominent Players:

Pfizer Inc.
Bristol-Myers Squibb Company
Johnson & Johnson Services
Inc.
AbbVie Inc.
Amgen Inc.
Novartis AG
AstraZeneca Plc UCB S.A.
Eli Lilly & Co
and Celgene Corporation

Role of Strong Product Pipeline & Mounting Clinical Research Investments

Over 20 drugs for psoriasis and psoriatic arthritis are currently in the phase II of pipeline, whereas more than 28 are in phase III of clinical trial, as indicated by the National Psoriasis Foundation. However, around 24 drugs have already received FDA approval for inclusion in the treatment for psoriasis and psoriatic arthritis.

While such a strong product pipeline continues to drive the demand for psoriasis and psoriatic arthritis treatment, a new research points to the shifting focus of several drug manufacturers to competitive pricing strategies, in an effort to attain widespread acceptance in coming years. Recently, Future Market Insights released a new intelligence based on the analysis of global psoriatic arthritis treatment market. The study forecasts a robust over-7% yearly growth for the market in 2019.

Industry Behemoths Cover More than 55% Market Value Share

In a fairly consolidated global landscape of psoriatic arthritis treatment market, more than 55% share of the total revenue is accounted by industry giants such as Novartis AG and AbbVie Inc. that include biologics in their core portfolio. While market leaders are maintaining focus on FDA approvals and clinical trials, research also points to the increasing importance of diverse pricing strategies.

Moreover, prominent players in psoriatic arthritis treatment market are likely to augment investments in R&D of biosimilars, biologics, and TNF (tumor necrosis factor) inhibitors to target regional markets. A number of leading drug manufacturers are also maintaining sizable investments in DMARDs that are scheduled for market entry in next few years. This is perceived as a strong factor improving growth prospects of psoriatic arthritis treatment market, according to the report.

Besides all these, strategic acquisitions, partnerships, and collaborations will remain the preferred expansion strategies adopted by a majority of prominent operators in psoriatic arthritis treatment landscape,” says a senior research analyst at the company.

Get a Customized Scope to Match Your Need Ask an Expert- https://www.futuremarketinsights.com/ask-question/rep-gb-2718

Demand for Biologics & DMARDs Gaining Momentum

Research-driven understanding of the pathophysiology of psoriatic arthritis is fueling the introduction of innovative therapies in psoriatic arthritis treatment market, triggering innovations among the market participants – thereby supporting the growth of psoriatic arthritis treatment market. Targeted biological therapy has been demonstrating a decent success rate in terms of inducing temporary pain relief resultant of psoriatic arthritis, and thus continues to represent an attractive position in the psoriatic arthritis treatment market.

The report says that the demand for biologics accounts for more than 55% share of the global market revenue, whereas DMARDs demand makes up for more than 3/4th of the total market value. Although a majority of psoriatic arthritis patients opt for injectable as a preferred route of administration of psoriatic arthritis treatment, increasing introduction of innovative oral drugs is uplifting the popularity of orally administered psoriatic arthritis treatment.

Development of novel oral treatments for psoriatic arthritis is likely to favor the growth of North America’s market. Growing availability of combination therapies and relatively economical biosimilar antibody therapeutics are identified to be the primary boosters for the growth of Europe’s market. Collectively, North America and Europe account for over 60% share in the global value of psoriatic arthritis treatment market. The report indicates that the psoriatic arthritis market in Asia Pacific is likely to display high growth potential in the course of next few years.

PSORIATIC ARTHRITIS (PSA) TREATMENT MARKET TAXONOMY

The global psoriatic arthritis (PsA) treatment market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach in front of the reader.

By Product

Non-steroidal anti-inflammatory drugs

Disease modifying Anti-rheumatic drugs

Corticosteroids

Antimalarial

Methotrexate

Others

Biologics

TNF Inhibitors

Interleukin inhibitors

By Route of Administration

Oral

Injectable

By Distribution Channel

Hospital pharmacies,

Retail pharmacies,

Mail order pharmacies

For critical insights, request for PDF Brochure: https://www.futuremarketinsights.com/reports/brochure/rep-gb-2718

Region

North America

Latin America

Europe

South Asia

East Asia

Oceania

Middle East & Africa

Adoption of donor egg IVF treatment accounted for the approximate revenue of US$ 2 billion in 2018, which are likely to witness a healthy spike by 6.7% in 2019. Future Market Insights (FMI) recently presented a research study on the global donor egg IVF market, according to which a majority of overall adoption is registered at fertility clinics and IVF centers.

A Majority of Patients Seek Donor Egg IVF Treatment at Fertility Clinics & IVF Centers

Donor egg IVF is a procedure in which technological and pharmacological manipulation is used to help and promote pregnancy, the procedure has gained significant ground globally, in recent years. Donor egg IVF has rapidly become one of the most sought after fertility treatment alternatives among the infertile population.

The study opines that fresh donor egg cycle has been preferred over frozen donor egg cycle, attributed to the associated high rates of pregnancy and successful births. Currently, nearly 70% of donor egg IVF treatment adoption is recorded at IVF centers and fertility clinics, and more than 70% of the times, the procedure is conducted by using fresh donor egg cycle.

In the fresh donor egg cycle, eggs are retrieved, following which they are fertilized immediately and directly transferred to the recipient’s womb (uterus). The birth rate and pregnancy rate by using fresh donor egg cycle are estimated to be more than 36% and 55%, respectively. On the flipside, the birth rate and pregnancy rate by using a frozen donor egg cycle are just about 24% and 39%, respectively. According to the report, enhanced pregnancy and birth rates will continue to advocate preference for fresh donor egg IVF over frozen.

To remain ‘ahead’ of your competitors, request for a sample

The Rising Burden of Infertility Pushing Scope of Egg Donor IVF Adoption

As concluded by FMI’s analysis, with an increasing number of couples postponing first pregnancy that generally leads to higher prevalence of age-related infertility issues, it is highly likely that procedures such as in-vitro fertilization (IVF) and a step ahead, donor egg IVF, will continue to witness robust demand in years to come.

Research has proven that the number of women with ovaries that have untimely ceased to function has been on a considerable rise over the recent past, and thus, donor egg remains the only chance for them to conceive and lead a successful pregnancy period. The increasing infertility burden is complemented by a strong increase in the number of female egg donors, which has been cited as another important factor pushing prospects of donor egg IVF market.

Europe’s donor egg IVF market is expected to witness strong growth in forthcoming years, followed by North America, as a result of high inbound of infertile population opting for fertility treatment, across the region. Moreover, the expensive costs of donor egg IVF treatment and favorable government initiatives and reimbursements on the same are accounting for prominence of these regions in global donor egg IVF industry. The report also indicates that donor egg IVF market in Asia Pacific will demonstrate high growth potential through the coming years, as a considerably large patient pool is seeking fertility solutions.

A majority of European countries offer good service at a reasonable budget for donor egg IVF procedures and some countries, such as Brazil and Australia, reimburse 50% of the treatment cost for unsuccessful donor egg IVF procedures, or reimburse other expenses such as accommodation or out-of-pocket costs for egg donors.

Get a Customized Scope to Match Your Need Ask an Expert- https://www.futuremarketinsights.com/ask-question/rep-gb-2499

DONOR EGG IVF (IN-VITRO FERTILIZATION) MARKET TAXONOMY
The global donor egg IVF market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach in front of the reader.

By Cycle Type

Fresh Donor Egg Cycle
Frozen Donor Egg Cycle

By End User

Direct / Patient
Hospitals
Fertility Clinics & IVF Centres

By Region

North America
Latin America
Europe
South Asia
East Asia
Oceania
Middle East & Africa

For critical insights, request for PDF Brochure: https://www.futuremarketinsights.com/reports/brochure/rep-gb-2499